Author

Lu Lv

Academy of Military Medical SciencesPrimary ORCID profile (0000-0003-2075-8620 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Lu LviD3 papers · Central South University

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:multiome· 1 Assay:proteomics· 1

Frequent Co-Authors

Lin LiiD· 2 shared Qing YeiD· 2 shared Yi-Jiao HuangiD· 2 shared Aiping WuiD· 1 shared Bei Sun· 1 shared Cheng‐Feng QiniD· 1 shared Hangyu ZhouiD· 1 shared Hao DuiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Lin LiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ribophorin-1 Governs Spike Abundance of Highly Pathogenic Coronaviruses by ER-associated degradation

Yi-Jiao Huang, Lu Lv, Wei Ran, Hongyun Zhao, Yong-Qiang Deng, Qing Ye, Lin Li, Xiao-Yan Wu, Qi Chen, Yi Hu, Bei Sun, Jianjun Zhao, Jincun Zhao, 秦成峰

This study identifies Ribophorin-1 as a host factor that reduces spike protein abundance on coronaviruses by promoting its degradation, thereby inhibiting infection.

bioRxiv · May 21, 2026 · PreprintMicrobiology

Viral protease-Initiated Pyroptosis Activator mRNA therapy as a Universal Antiviral Strategy

Lin Li, Xiuli Yan, Haoyang Wang, Hangyu Zhou, Yuyan Li, Jian Li, Rongrong Zhang, Lu Lv, Xing‐Yao Huang, Hao Du, Tian-Shu Cao, Qing Ye, Hui John Zhao, Yan Fu, Aiping Wu, , Cheng‐Feng Qin

This paper develops VIPA mRNA therapy, which uses viral protease-initiated pyroptosis to suppress viral replication and elicit immune responses in animal models.

bioRxiv · Nov 14, 2025 · PreprintMicrobiology